INTRECOM Overview
- Industry
- Biotechnology Research
- Employees
- 31
- Founded
- 2022
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
About INTRECOM
Patients with Locked-In Syndrome (LIS) are completely paralysed and unable to communicate. This is an intolerable, fearful situation with very low quality of life and extreme burden of care for patients, family, and care givers. INTRECOM will provide a breakthrough for these patients by developing a novel, fully implantable Brain-Computer Interface (BCI) technology that allows for real-time speech decoding and use in the home environment. This BCI system will significantly transcend current technology by providing a high-resolution and sustainable device, combining state-of-the-art hardware and software solutions based on Artificial Intelligence (AI) to liberate LIS patients from their isolation.